Mirae Asset Global Investments Co. Ltd. Acquires 34,549 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Mirae Asset Global Investments Co. Ltd. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 434,165 shares of the biopharmaceutical company's stock after buying an additional 34,549 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Gilead Sciences were worth $40,689,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of GILD. Algert Global LLC bought a new stake in Gilead Sciences in the 2nd quarter valued at about $254,000. AMF Tjanstepension AB boosted its stake in shares of Gilead Sciences by 14.7% in the third quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company's stock valued at $33,645,000 after buying an additional 51,390 shares during the period. Czech National Bank grew its position in Gilead Sciences by 6.8% during the third quarter. Czech National Bank now owns 253,618 shares of the biopharmaceutical company's stock worth $21,263,000 after buying an additional 16,209 shares in the last quarter. GAMMA Investing LLC increased its stake in Gilead Sciences by 53.7% during the 3rd quarter. GAMMA Investing LLC now owns 15,273 shares of the biopharmaceutical company's stock worth $1,281,000 after acquiring an additional 5,333 shares during the period. Finally, Diversified Trust Co raised its holdings in Gilead Sciences by 1.4% in the 3rd quarter. Diversified Trust Co now owns 33,436 shares of the biopharmaceutical company's stock valued at $2,803,000 after acquiring an additional 449 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Down 2.0 %

GILD stock traded down $2.00 during midday trading on Friday, hitting $96.04. The stock had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market cap of $119.69 billion, a P/E ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The business has a fifty day moving average price of $93.04 and a two-hundred day moving average price of $86.65. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $100.51.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.29 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Maxim Group cut shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Cantor Fitzgerald reiterated a "neutral" rating and set a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. Barclays boosted their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a research report on Thursday, November 7th. Finally, UBS Group raised their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a "neutral" rating in a report on Thursday, November 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $98.39.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company's stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 572,824 shares of company stock worth $53,611,715. Corporate insiders own 0.16% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.